论文部分内容阅读
为了比较培美曲塞联合顺铂与多西他赛联合顺铂二线治疗晚期肺腺癌的临床疗效,将符合入组标准的68例晚期肺腺癌患者随机分为观察组与对照组,每组34例。观察组以培美曲塞联合顺铂化疗,对照组多西他赛联合顺铂化疗。治疗后,CR两组均为0,两组相比差异无统计学意义,P>0.05。疾病控制率(DCR),观察组为23.53%,对照组为20.59%,两组相比差异无统计学意义,P>0.05。毒副反应Ⅱ～Ⅳ级发生率观察组低于对照组,差异有统计学意义,P<0.05。培美曲塞联合顺铂二线治疗肺腺癌临床疗效与多西他赛联合顺铂二线治疗晚期肺腺癌的临床疗效相当,但毒副反应发生率降低。
In order to compare the clinical efficacy of pemetrexed combined with cisplatin and docetaxel plus cisplatin in the treatment of advanced lung adenocarcinoma, 68 patients with advanced adenocarcinoma of the lung that meet the inclusion criteria were randomly divided into observation group and control group, Group of 34 cases. Observation group pemetrexed combined with cisplatin chemotherapy, the control group docetaxel combined with cisplatin chemotherapy. After treatment, both groups were 0 CR, no significant difference between the two groups, P> 0.05. The disease control rate (DCR) was 23.53% in the observation group and 20.59% in the control group. There was no significant difference between the two groups (P> 0.05). The incidence of grade Ⅱ ~ Ⅳ toxicosis in observation group was lower than that in control group, the difference was statistically significant, P <0.05. Pemetrexed combined with cisplatin second-line treatment of lung adenocarcinoma clinical efficacy and docetaxel combined cisplatin second-line treatment of advanced lung adenocarcinoma clinical efficacy, but the incidence of adverse reactions decreased.